Author contributions: L.S.: conception and design, data analysis and interpretation; K.A.: collection and/or assembly of data, data analysis and interpretation; H.Z.: provision of study material or patients, collection, and/or assembly of data; T.Y.: collection and/or assembly of data, data analysis and interpretation; Y.H.: data analysis and interpretation; S.Z.: collection and/or assembly of data; T.X.: collection and/or assembly of data; A.L. and S.S.: conception and design, data analysis and interpretation, manuscript writing. L.S. and K.A. contributed equally to this article.
First published online in STEM CELLSExpress March 19, 2009
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that, despite the advances in immunosuppressive medical therapies, remains potentially fatal in some patients, especially in treatment-refractory patients. Here, we reported that impairment of bone marrow mesenchymal stem cells (BMMSCs) and their associated osteoblastic niche deficiency contribute in part to the pathogenesis of SLE-like disease in MRL/lpr mice. Interestingly, allogenic BMMSC transplantation (MSCT) is capable of reconstructing the bone marrow osteoblastic niche and more effectively reverses multiorgan dysfunction when compared with medical immunosuppression with cyclophosphamide (CTX). At the cellular level, MSCT, not CTX treatment, was capable to induce osteoblastic niche reconstruction, possibly contributing to the recovery of regulatory T-cells and reestablishment of the immune homeostasis. On the basis of the promising clinical outcomes in SLE mice, we treated four CTX/glucocorticoid treatment-refractory SLE patients using allogenic MSCT and showed a stable 12–18 months disease remission in all treated patients. The patients benefited an amelioration of disease activity, improvement in serologic markers and renal function. These early evidences suggest that allogenic MSCT may be a feasible and safe salvage therapy in refractory SLE patients. STEM CELLS 2009;27:1421–1432
Systemic lupus erythematosus (SLE) is a common and potentially fatal autoimmune disease in characterized by antibodies associated multiorgan injuries including renal, cardiovascular, neural, musculoskeletal, and cutaneous systems . The pathology of SLE involves the destruction of targeted organ tissues and accumulation of autoreactive lymphocytes and immune complexes. Although disease severity and organ involvement vary significantly among SLE patients, abnormalities of T and B lymphocytes are universal [1–3]. Moreover, SLE manifests multifaceted immune modulation, including both deficiency and hyperactivity of the immune system. A deeper understanding of the underlying pathology is crucial to develop optimal therapies for the restoration of immune homeostasis without compromising the protective immune response to pathogens .
In addition to conventional medical therapies such as cyclophosphamide (CTX) and mycophenolate mofetil, several new strategies have been developed targeting specific activation pathways relevant to SLE pathogenesis [1, 5]. For instance, B-cell–depleting therapies using the monoclonal antibodies rituximab and epratuzumab have benefited a specific subpopulation of lupus patients . Recently, hematopoietic stem cell transplantation has been reported to improve disease activity in treatment-refractory SLE patients  and reverse organ dysfunction in several animal models . Despite improved supportive care, aggressive immunosuppressive medical therapies, and new therapeutic interventions, a subset of SLE patients continues to suffer significant morbidity and mortality from active disease, with visceral organ involvement. Therefore, it is urgent to develop more effective therapy for SLE disorder, especially for treatment-refractory patients.
Bone marrow mesenchymal stem cells (BMMSCs) are multipotent stem cells capable of differentiating into a variety of cell types including osteoblasts, chondrocytes, adipocytes, and myoblasts [9–11]. The BMMSC/osteoblast lineage plays a critical role in maintaining the hematopoietic stem cell (HSC) niche [12–14] and modulating immune cells including T and B lymphocytes, dendritic cells, and natural killer cells [15–20]. Transplantation of ex vivo-expanded BMMSCs proved effective in treating acute graft-versus-host-disease (GVHD) by inhibiting T lymphocyte function [21–23] and ameliorating HSC engraftment [24, 25]. A recent convergence of clinical and basic research has highlighted the potential of using BMMSCs to treat immune diseases . In this study, we found that deficiency of BMMSC/osteoblast function in SLE mouse model leads to impairment of the osteoblastic niche, which may correlate in part, to difficulty of reconstructing immune homeostasis in treatment-refractory SLE patients. Allogenic BMMSC transplantation (MSCT) conferred significant therapeutic effects on SLE mice and treatment-refractory patients by reconstructing the osteoblastic niche and restoring immune homeostasis.
MATERIALS AND METHODS
Female C3MRL-Faslpr/J (MRL/lpr) and background matched C3H/HeJ mice were purchased from the Jackson Laboratory (Bar Harbor, ME, http://www.jax.org). Female immunocompromised mice (Beige XIDIII nude/nude) were purchased from Harlan (Indianapolis, IN, http://www.harlan.com). All animal experiments were performed under an institutionally approved protocol for the use of animal research (USC #10874 and #10941).
All antibodies used in this study were described in “Materials and Methods” section in supporting information.
Bone Phenotype Analysis.
Microcomputed tomography (microCT) and peripheral quantitative CT analyses were performed as previously described . Detailed methods are described in “Materials and Methods” section in supporting information. Paraffin sections were used for histological analysis, including H&E staining, tartrate-resistant acid phosphatase (TRAP) staining, and immunohistochemistry as described in “Materials and Methods” section in supporting information.
Isolation and Culture of Mouse BMMSCs.
Mouse BMMSCs were isolated and cultured as described previously . The details are described in “Materials and Methods” section in supporting information.
Allogenic Mouse BMMSC Transplantation into MRL/lpr Mice.
Under general anesthesia, C3H/HeJ-derived BMMSCs (0.1 × 106 cells per 10 g body weight) were infused into MRL/lpr mice via tail vein at different ages of 9 weeks (n = 12) and 16 weeks (n = 12). In control group, MRL/lpr mice (9-week-old) received phosphate-buffered saline (n = 12) or CTX monohydrate (Sigma, St. Louis, MO, http://www.sigmaaldrich.com) (200 μg/g body weight) (n = 12) and age-matched C3H/HeJ mice (n = 12) were used. All mice were sacrificed at 20 weeks of age for further analysis.
Four patients (three female and one male) at age 16, 17, 20, and 23 were treated with CTX (0.75 g/m2 per month) and prednisone (≥20 mg/day) for more than 6 months. The treatment was ineffective in these patients as shown the SLE disease activity index (SLEDAI) more than eight  and lupus nephritis (24 hours urine protein ≥ 1 g and/or serum creatinine ≥ 1.5 mg/dl) without end-stage renal failure. Four healthy patients' relatives, at age 19 (male), 42 (male), 43 (male), and 46 (female) were selected as donors. All of the recipients and donors gave informed consent to enroll in the clinical study. This clinical study was approved by the Ethics Committee of the Affiliated Drum Tower Hospital of Nanjing University Medical School and registered at ClinicalTrials.gov (Identifier: NCT00698191).
Culture and Expansion of Human BMMSCs.
Human bone marrow aspirates were collected from iliac of four donors and two SLE patients. The details are described in “Materials and Methods” section in supporting information.
Allogenic Human BMMSC Transplantation in SLE Patients.
Donor BMMSCs from patients' family members were intravenously infused in eligible SLE recipients (≥1 × 106/kg body weight). Prednisone 20–30 mg was administrated to recipient patients prior to the MSCT procedure. Post MSCT maintenance therapy includes a tapering dose of steroid and CTX, with two patients completely off CTX at 5–6 months. Specific maintenance therapy for all the four patients are as follows: (a) patient#1: prednisone 10 mg/day and CTX 0.6 g/every 2 months for 6 months, then prednisone 5 mg/day and CTX 0.6 g/every 2 months for 12 months; (b) patients #2: prednisone 10 mg/day and CTX 0.6g/every 2 months for 7 months, then prednisone 10 mg/day with no CTX for 5 months; (c) patients #3: prednisone 10 mg/day and CTX 0.6g/every 2 months for 7 months, then prednisone 5 mg/day and CTX 0.6g/every 2 months for 5 months; and (d) patients #4: prednisone 10 mg/day and CTX 0.6g/every 2 months for 6 months, then prednisone 10 mg/day with no CTX for 6 months.
Colony Forming Unit Fibroblast Assay.
Colony-forming unit fibroblast (CFU-F) assay was performed according to previous study ( and “Materials and Methods” section in supporting information).
Cell Proliferation Assay.
The proliferation of BMMSCs was evaluated by bromodeoxyuridine (BrdU) incorporation as previously described in ( and in “Materials and Methods” section in supporting information).
In Vitro Differentiation Assay.
In vitro osteogenic and adipogenic induction of mouse BMMSCs were performed as described previously ( and “Materials and Methods” section in supporting information).
In Vivo Bone Formation Assay.
BMMSCs were subcutaneously transplanted into immunocompromised mice using hydroxyapatite tricalcium phosphate (HA/TCP) as a carrier . Detailed methods were described in the “Materials and Methods” section in supporting information. At 8 weeks post-transplantation, the transplants were harvested for histological analysis (“Materials and Methods” section in supporting information).
Total RNA was isolated from cultures. The cDNA was amplified with specific primers (“Materials and Methods” section in supporting information). The specific primers are listed on supporting information Table 1.
Western Blot Analysis.
Western blot analysis was performed as described previously . Detailed methods are described in “Materials and Methods” section in supporting information.
Measurement of Biomarkers in Blood Serum, Urine, and Spleen.
Peripheral blood serum, urine samples, and total protein from spleen were collected from mice. Autoantibodies, albumin, immunoglobulins, runt-related NF-κB ligand (RANKL), C-terminal telopeptides of type I collagen, interleukin 6 (IL-6), IL-17, and transforming growth factor beta (TGFβ) in the serum and spleen were analyzed by enzyme-linked immunosorbent assay (ELISA) (see “Materials and Methods” section in supporting information). The protein concentration in urine was measured using Bio-Rad Protein Assay (Bio-Rad, Hercules, CA, http://www.bio-rad.com). Peripheral blood serum and urine samples collected from SLE patients were corrected to measure serum complement component three (C3), blood urea nitrogen, and urine protein levels in the Clinical Laboratory at the Drum Tower Hospital of Nanjing University Medical School according the laboratory's instructions.
Histological Analysis of Kidney, Liver, and Spleen.
Kidney, liver, and spleen were harvested from mice and fixed. The sections were used for further experiments (“Materials and Methods” section in supporting information).
Histomorphometric analysis was quantified as described previously [26, 27]. Detailed methods are described in “Materials and Methods” section in supporting information.
CD4+ T Lymphocyte Isolation.
CD4+ T lymphocytes were isolated from mouse spleen using a magnetic sorter and mouse CD4+ T lymphocyte isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany, http://www.miltenyibiotec.com) following manufacture's instruction. The purity of the CD4+ T-cells was >95%.
Flow Cytometric Analysis.
Flow cytometric staining and analysis were performed as previously reported ( and “Materials and Methods” section in supporting information).
Student's t test was used to analyze significance between two groups. p value of less than .05 was considered as a significant difference.
SLE Model MRL/Lpr Mice Showed BMMSC Impairment and Osteoblastic Niche Deficiency
Osteoporosis is commonly reported in SLE patients secondary to long-term use of glucocorticoids and CTX . We verified the osteoporotic changes in the skeletal structures of naïve CD95-mutant MRL/lpr mice by microradiographic and bone morphometric analyses. The femurs of MRL/lpr mice at age of 20 weeks showed remarkable reduction in bone mineral density (BMD) (Fig. 1A) and significant atrophy of trabecular bone (Fig. 1B) with reduced bone volume (Fig. 1C), trabecular number (Fig. 1D), bone surface area (Fig. 1E), and increased trabecular separation (Fig. 1F). These findings indicated that the skeletal system of naïve MRL/lpr mice undergoes changes typical of osteoporosis phenotype.
As T-lymphocyte over-activation has been associated with BMMSC impairment and osteoporosis [26, 30, 31], we next examined whether T-lymphocytes are over-activated in MRL/lpr mice and their effects on BMMSCs. We showed that BMMSCs derived from MRL/lpr mice (MRL/lpr-BMMSCs) displayed an increase in the number of CFU-Fs, representing the number of clonogenic mesenchymal progenitors, as compared to control mice (Fig. 1G), and an elevated proliferation rate by BrdU incorporation assay (Fig. 1H). MRL/lpr-BMMSCs also showed impairment of osteogenic differentiation, shown here as a decreased mineralization in osteo-inductive cultures (Fig. 1I), and decreased levels of osteogenic gene expression, including runt-related transcription factor two (Runx2), alkaline phosphatase (ALP), and osteocalcin (OCN) assessed by both semiquantitative reverse transcription polymerase chain reaction (RT-PCR) (Fig. 1J) and Western blot analyses (Fig. 1K). The in vitro findings were further confirmed with in vivo studies in immunocompromised mice (Fig. 3D), showing reduced bone nodule formation when subcutaneously transplanted using HA/TCP as a carrier. Additionally, MRL/lpr-BMMSCs demonstrated impairment of adipogenic differentiation as shown by decreased numbers of lipid-specific Oil red O-positive cells (Fig. 1L) and reduced expression of adipocyte-specific genes, peroxisome proliferator-activated receptor γ2 (PPARγ2), and lipoprotein lipase (LPL) by semiquantitative RT-PCR (Fig. 1M). These findings suggest that BMMSCs derived from MRL/lpr mice were functionally impaired compared with control mice.
In contrast to BMMSC/osteoblast lineage, osteoclasts play a significant role in the maintenance of bone homeostasis by their bone resorption function. We examined osteoclast activity in MRL/lpr mice and found an increased number of TRAP+ osteoclasts in the distal femur epiphysis of MRL/lpr mice (Fig. 1N), elevated serum levels of RANKL, a critical factor for osteoclastogenesis, (Fig. 1O), and bone resorption marker C-terminal telopeptides of type I collagen (Fig. 1P) when compared with control mice. These findings revealed that over-activated osteoclasts in MRL/lpr mice potentially contribute to bone loss in SLE-like disease.
Allogenic MSCT Improves Multiple Organ Function in MRL/Lpr Mice
SLE-like multisystemic autoimmune disorders usually appear at age 7-8 weeks in MRL/lpr mice. To explore the effects of early versus late treatment interventions, we infused allogenic BMMSCs into MRL/lpr mice either at an early stage of the SLE disorder (9 weeks of age, MSCT9), or at the matured stage (16 weeks of age, MSCT16) (Fig. 2A). CTX treatment at 9 weeks of age was used as a conventional treatment control (Fig. 2A). It has been reported that autoantibodies play a crucial role in multiple organ impairment in SLE patients . Consistent with human findings, MRL/lpr mice showed a remarkable increase in circulating autoantibodies, specifically anti-double-strand DNA (dsDNA) IgG and IgM antibodies (Fig. 2B), anti-nuclear antibody (ANA) (Fig. 2C), and immunoglobulins including IgG1, IgG2a, IgG2b, and IgM (supporting information Fig. 1A) in the peripheral blood. Initiating MSCT at both early and matured stages, 9- and 16-week-olds, benefited a significantly reduction in serum levels of anti dsDNA antibody IgG and IgM, ANA, immunoglobulins IgG1, IgG2a, IgG2b, and IgM (Fig. 2B, 2C, supporting information Fig. 1A). In addition, decreased serum albumin levels in MRL/lpr mice were observed after MSCT (Fig. 2D). When compared with MSCT, conventional CTX treatment only partially reduced levels of serum autoantibodies, immunoglobulin IgG2a, and recovered albumin level in MRL/lpr mice (Fig. 2B–2D, supporting information Fig. 1A). In addition, unlike MSCT, CTX treatment failed to reduce circulating immunoglobulins IgG1, IgG2b, and IgM in MRL/lpr mice (supporting information Fig. 1A).
As expected, MRL/lpr mice showed renal disorders such as nephritis with glomerular basal membrane disorder, mesangial cell overgrowth, deposition of C3 and IgG, and infiltration of CD3-positive cells (Fig. 2E). In addition, we found presence of increments of urine protein (Fig. 2F) and immunoglobulins including IgG1, IgG2a, IgG2b, and IgM in MRL/lpr mice (Fig. 2G). In general, MSCT at both early and matured stages was able to improve renal disorders (Fig. 2E–2G), specifically restoring kidney glomerular structure, and reducing C3 and glomerular IgG deposition (Fig. 2E). Moreover, ELISA data showed that MSCT was able to elevate serum C3 level and reduce urine C3 level (supporting information Fig. 1B). Although CTX treatment could reduce glomerular IgG deposition, it did not restore the glomerular structure and C3 accumulation when compared with MSCT (Fig. 2E, supporting information Fig. 1B). In response to either MSCT or CTX treatment, MRL/lpr mice showed reduced urine protein levels at 4 weeks post treatment (Fig. 2F). However, MSCT, but not CTX treatment, was capable to completely restore renal function, shown as normalization of serum and urine creatinine levels in MRL/lpr mice, in comparison to disease-free control mice (supporting information Fig. 1C). These experimental evidences indicated that MSCT is a superior therapeutic approach for treating nephritis in MRL/lpr mice and capable to restore renal function.
Further histological analysis with H&E, Oil red O, and Periodic Acid-Schiff staining revealed presence of inflammatory cells infiltrates in the portal triads, fatty degeneration, and glycogen degradation in hepatocytes (supporting information Fig. 2), suggesting liver impairment in MRL/lpr mice. Interestingly, MSCT at two stages, as well as CTX treatment, were capable to reverse all SLE-associated histological changes in the liver (supporting information Fig. 2). These findings indicate that MSCT-associated suppression of autoantibodies may partly contribute to the amelioration of multiorgan dysfunction in MRL/lpr mice.
Allogenic MSCT Ameliorates Osteoporosis-Like Phenotype in MRL/Lpr Mice, and Improves the Osteoblastic Niche
To examine whether MSCT is capable of recovering skeletal disorder in MRL/lpr mice, we analyzed the bone phenotype and BMMSC function in MSCT-treated MRL/lpr mice compared with CTX-treated and nontreated mice. Bone histomorphometric analysis with H&E and TRAP staining revealed that MSCT at both early and matured stages was capable of promoting trabecular bone formation and inhibiting osteoclastogenesis (Fig. 3A and supporting information Fig. 3A, 3B). A balance between bone formation and resorption is necessary for maintaining bone integrity. It has been recognized that osteoblasts, differentiated from their progenitor BMMSCs, contribute to niche organization for HSC in the bone marrow compartment [12–14]. Consistent with this observation, we showed that MSCT significantly improved osteoblastic niche reconstruction in MRL/lpr mice (Fig. 3B) evidenced by an increase in new bone and marrow formation. However, CTX treatment was not able to improve bone volume and reconstruct osteoblastic niche (Fig. 3A, 3B), but slightly suppress osteoclastogenesis (supporting information Fig. 3A, 3B). At the molecular level, the expression of osteoprotegerin (OPG) and RANKL were downregulated and upregulated in splenocytes of MRL/lpr mice, respectively (supporting information Fig. 4). MSCT was capable to restore OPG and suppress RANKL expression in MRL/lpr mice. However, CTX treatment only suppressed RANKL (supporting information Fig. 4).
BMMSCs isolated from MSCT-treated MRL/lpr mice showed restoration of osteogenic differentiation demonstrated as an increase in calcium deposition (supporting information Fig. 5A), elevated levels of osteogenic genes and proteins, including ALP and OCN (supporting information Fig. 5B, 5C), under osteogenic inductive conditions. CTX treatment mildly promoted osteogenic differentiation, but was not able to restore changes in the osteogenic genes in MRL/lpr mice (supporting information Fig. 5). BMMSCs derived from MSCT-treated MRL/lpr mice showed significantly increased new bone formation (Fig. 3C, 3D) and osteoblastic niche regeneration (Fig. 3C, 3E) when transplanted into immunocompromised mice. In addition, MSCT appeared to suppress the high colony formation of BMMSCs derived from MRL/lpr shown as a significant reduction in number of CFU-F in treated mice (Fig. 3F). CTX treatment showed similar treatment effects to MSCT, however, at a lower extent (Fig. 3C, 3E and supporting information Fig. 5). These findings suggest that allogenic MSCT provided an optimal therapy for improving bone volume and BMMSC function in MRL/lpr mice when compared with conventional CTX.
Allogenic MSCT Restores the Immune System via CD4+CD25+Foxp3+ cell, Th17 Cells, and Plasma Cells
It has been suggested that CD4+CD25+Foxp3+ cells prevent pathogenic autoimmunity by suppressing proliferation and production of pro-inflammatory cytokines in effector immune cells, such as helper T-lymphocytes . In contrast, Th17 cells, an inflammatory IL17 producing cell, have been linked to the pathogenesis of autoimmune diseases  and bone destruction . To explore whether MSCT affects the immune balance between CD4+CD25+Foxp3+ cells and Th17 cells in SLE-like disorders, we studied Foxp3+ cells and Th17 cells in spleen and bone marrow of MRL/lpr mice. MSCT at both early and matured stages was able to restore Foxp3+ cells in MRL/lpr mice (Fig. 4A). However, CTX treatment only slightly increased the level of Foxp3 (Fig. 4A). Immunohistochemical analysis showed that IL17-positive cells were significantly increased in bone marrow and spleen of MRL/lpr mice when compared with control mice, and were specifically suppressed by MSCT (Fig. 4B, 4C). Flow cytometry also demonstrated that the increased in CD4+IL17+ T-lymphocytes in bone marrow and spleen of MRLlpr mice was significantly reduced by MSCT at both early and matured stages, when compared with CTX treatment (Fig. 4E). Semiquantitative RT-PCR analysis further confirmed the decreased IL17 gene expression in both bone marrow and spleen of MSCT mice (Fig. 4D, 4F). Likewise, CTX treatment also reduced IL17 levels in MRL/lpr mice (Fig. 4B–4F). Moreover, ELISA analysis showed that IL17 levels were remarkably increased in spleen of MRL/lpr mice and MSCT, but not CTX treatment, significantly suppressed the elevated IL17 levels (Fig. 5A).
As MSCT is capable of suppressing the levels of autoantibodies in MRL/lpr mice, we examined whether MSCT regulates CD138-positive plasma cells, an immunoglobulin producing cell. In MRL/lpr mice, CD138-positive cells were significantly increased compared with control mice by immunohistochemistry (Fig. 5B). MSCT reduced the number of CD138-positive cells in MRL/lpr mice (Fig. 5B). ELISA also showed that allogenic MSCT was able to reduce the levels of anti-dsDNA IgG and immunoglobulins, IgG1, IgG2a, IgG2b, and IgM, in spleen of MRL/lpr mice (Fig. 5C, 5D). Although CTX appeared capable of inhibiting the number of CD138-positive cells and the production of both autoantibodies and immunoglobulins, this conventional treatment was not as effective as MSCT (Fig. 5B, 5C). These results suggest that allogenic MSCT is a more improved therapy with a better treatment effect than conventional CTX in SLE-like MRL/lpr mice, possibly through the modulation of multiple immune cells.
BMMSCs Derived from SLE Patients Showed Osteogenic Impairment
Previous study suggested that BMMSCs from SLE patients might show differentiation impairment similar to those observed in SLE mice . To verify the findings in humans, we isolated BMMSCs from two SLE patients and characterized their osteogenic differentiation properties in vivo using subcutaneous transplantation in immunocompromised mice. BMMSCs derived from SLE patients showed significantly decreased bone forming capacity and impaired reconstruction of bone marrow in vivo when compared with BMMSCs from matched normal healthy subjects (Fig. 6A). Furthermore, semiquantitative RT-PCR analysis revealed decreased expression of osteogenic genes Runx2 and OCN in BMMSCs from SLE patients (Fig. 6B). Given the evidence that some advanced stage SLE patients may have experienced a suppression of CD34+ bone marrow cells , it is postulated that the decrease in CD34+ subset may correlate with the osteoblastic niche deficiency in the bone marrow of SLE patients.
Allogenic MSCT Is a Safe and Feasible Salvage Therapy in Patients with Refractory SLE
As our animal study showed that MSCT, but not CTX treatment, offered improved clinical outcomes and reversed multiorgan dysfunction in SLE, we hypothesized that MSCT may be capable of curing CTX-refractory SLE patients. To test this hypothesis, we conducted a pilot clinical study to assess the efficacy and safety of MSCT in a small cohort group of SLE patients. Three female and one male patients in the age range of 16–23 years old, with treatment-refractory SLE for duration of 12–51 months were enrolled for allogenic MSCT (Table 1). All subjects met the revised criteria for SLE established by the American College of Rheumatology (ACR, 1997) and had been previously treated with CTX and high-dose of prednisone (more than 20 mg/day) (Table 1). Patient eligibility criteria also included lupus glomerulonephritis (class III, IV, V) with severe elevation of increment of 24-hour urine protein levels and/or serum creatinine ≥1.5 mg/dl. Bone marrow was collected from patients' healthy family member and ex vivo expanded in culture under GLP/GMP protocols. MSCT were infused at ≥1 × 106 cells per kg body weight. Primary outcomes were overall survival and disease remission defined as requiring no further high-dose of immunosuppressive medications except the low maintenance doses of corticosteroids and CTX. Post MSCT maintenance therapy includes a tapering dose of steroid and CTX, with two patients completely off CTX at 6 months, and two patients on low-dose of CTX at 0.6 mg/every 2 months. Secondary outcomes included SLEDAI , complement C3, and renal function monitored by 24-hour urine protein and serum creatinine levels. Our short-term clinical outcome in 12–18 months follow-up post-MSCT showed no allogenic MSCT-related complications including cardiovascular, pulmonary insufficiencies, infection, malignancy, and metabolic disturbances. Assessment of SLEDAI indicated the improvement of disease activity in all allogenic MSCT-treated patients at each follow-up period (Fig. 6D). All recipients were followed up for 12–18 months and showed recovery of kidney function with low baseline 24-hour urine protein levels (Fig. 6E). Serum C3 level improved at one-month post MSCT in all patients, from 0.4775 ± 0.1134 to 0.7750 ± 0.0826 g/L. These early clinical data demonstrate safety and efficacy of MSCT in SLE patients and improvement of disease activities at post allogenic MSCT. Further long-term follow ups and additional patient enrollment are in progress.
Table 1. Patient information
Interestingly, we also found increased levels of CD4+Foxp3+ cells followed allogenic MSCT in 3 SLE patients with statistical significance at 3-month post MSCT (Fig. 6F). The MSCT-associated increased level of CD4+Foxp3+ cells in these treated patients correlates with similar findings of recovery of Foxp3+ cells in MRL/lpr mice followed MSCT (Fig. 4A). Further studies are needed to uncover the underlying mechanisms of MSCT induced immune regulation in ameliorating SLE disease activities in refractory patients.
Clinically, BMMSCs have been successfully utilized to treat a variety of human diseases such as bone fracture , severe aplastic anemia , and acute GVHD , suggesting that BMMSCs are a promising population of postnatal stem cells for clinical therapies. In this study, we used MRL/lpr mice as a SLE mouse model to investigate the role of the BMMSC/osteoblast lineage in SLE disorder and compared MSCT mediated therapy to conventional CTX treatment in SLE. MRL/lpr mice were generated by the insertion of the early transposable element ETn in the Fas gene, which causes a striking reduction in Fas mRNA expression and is associated clinically with marked acceleration of the lupus-like disease . Levels of circulating immune complexes rise enormously from about 3 months of age in MRL-lpr/lpr but not in MRL mice. In addition, a markedly increase in serum interleukin 12 (IL-12) and nitric oxide have been attributed to the development of autoimmunity . Although SLE mice have been well-characterized , we identified a significant osteoporosis phenotype marked by elevated osteoclast activity, as seen in estrogen deficient osteoporosis , and impairment of BMMSCs caused by T-cell over-activation . The deficiency of BMMSCs in SLE conditions supports the rationale of using allogenic, not autologous, BMMSCs for SLE treatment in this study. Recognizing that the bone marrow microenvironment in SLE can potentially injure osteoblasts and their progenitor BMMSCs [36, 44], we hypothesized that osteoblastic niche dysfunction might contribute to the pathology of SLE and therefore restoration of the SLE-impaired niche will provide a better treatment outcome. As the BMMSC/osteoblast lineage plays an important role in regulating the immune function and maintaining the HSC niche [15–20], reestablishment of the osteoblastic niche can improve the overall immune function as seen in allogenic MSCT-treated mice showing improvement of Foxp3+ cells, Th17 cells, and plasma cells. Overall, MSCT resulted in better therapeutic outcomes than CTX treatment, specifically improving immune system, recovering renal function, and restoring SLE-degenerative changes in multi-organs, including the skeletal, renal, and hepatic systems, in MRL/lp. The new cell-based therapeutic approach appears more effective than conventional therapy without the drug-related cytotoxicities. Supported by the clinical benefits of MSCT in SLE mice , we tested the feasibility of MSCT in a small defined group of CTX-refractory SLE patients. A possible explanation that MSCT showed superior therapeutic effect to CTX may associate with the fact that MSCT, but not CTX, is capable of recovering bone formation and marrow genesis and therefore, contributing to the reorganization of the osteoblastic niche. CD4+Foxp3+ cells are naturally occurring suppressor T-cells that regulate a wide variety of immune functions and provide protection from autoimmune diseases, GVHD, transplant rejection, and overwhelming tissue destruction during infections. Thus, CD4+ Foxp3+ cells are critical in the induction and maintenance of immune tolerance . Foxp3 is developed as a specific marker of natural regulatory T-cells and induced regulatory T-cells [47–49]. In animal studies, the induction of Foxp3 positive T-cells markedly reduces autoimmune disease severity in models of diabetes, multiple sclerosis, asthma, inflammatory bowel disease, thyroiditis, and renal disease . In human disease, alterations in numbers and functions of Foxp3-expressed cells are found in a number of diseases such as SLE . Our data showed that MSCT restored Foxp3+ cell levels in both MRL/lpr mice and SLE patients. The combination treatment using MSCT with CTX in the SLE mice failed to yield an optimal therapeutic effect as compared to MSCT in terms of BMD improvement (data not shown).
Lupus nephritis is one of the major complications of SLE disorder and its treatment remains a clinical challenge. Classical immunosuppressive agents were able to slow the progression to end-stage renal failure but do not target specific immune dysfunctions . The patients with treatment-refractory SLE enrolled in this study failed to maintain adequate renal functions secondary to lupus nephritis. MSCT treatment significantly improved renal function in these patients, and maintained an improved overall survival and disease remission during the current follow ups.
HSC transplantation has shown promising results in treating SLE patients. Because allogenic BMMSC from a patient's family member without human leukocyte antigen match is an easily accessible stem cell resource, MSCT may offer another effective cell therapy with fewer side effects. In our 12–18-month follow-up period, we did not find any clinical signs of adverse effects. The therapeutic outcomes of allogenic MSCT were significant in patients with treatment-refractory SLE shown as reduced SLEDAI score, urine protein level, and improved quality of life. In addition, MSCT may be valuable at different stages of SLE, as we administered MSCT to MRL/lpr mice at both early and matured stages of SLE and their therapeutic effects were almost the same.
In this study, we demonstrated that SLE is associated with osteoblastic niche deficiency and proposed a new ready-to-use cell-based therapeutic approach for SLE patients that may directly target the immune system. Allogenic MSCT ameliorates SLE through multiple mechanisms, including reestablishing the osteoblastic niche, recovering Foxp3+ cells, and downregulating Th17 levels. Using a small pilot clinical study, we have demonstrated early promising findings supporting the efficacy and safety of using allogenic MSCT in patients with treatment-refractory SLE during our short-term follow ups. Further long-term follow ups are in progress and our study is currently in the active recruiting phase to further confirm the efficacy and safety of MSCT as a new treatment modality in SLE.
This research was supported by the grant from California Institute for Regenerative Medicine (RN1-00572 for S.S. and A.L.) and the grants from NIDCR/NIH R01DE017449 and R21 DE017632 (to S.S. for animal study) for animal studies, and partially supported by the National Natural Science Foundation of China (No. 30772014 for L.S.), the Chinese Education Ministry (20050315001 for L.S), and the Jiangsu Province 135 Talent Foundation (RC2007002 for L.S.). We thank Dr. Larry Fisher at NIDCR/NIH for providing ALP and OCN antibodies.
DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST
The authors indicate no potential conflicts of interest.